CliffBio
small molecule

ZYKADIA

CERITINIB

Loss of exclusivityDecember 2037latest FDA-listed patent expiry
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameZYKADIA
Active ingredientCERITINIB
Strength150MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2019
Marketing statusRX

Listed patents

PatentExpiresType
12357630December 2037use U-3096
8703787February 2032use U-1179
9309229January 2032substance, product
8039479June 2030substance, product
7964592April 2028substance, product
8399450November 2027substance, product
8377921November 2027use U-1179
7893074April 2026substance, product

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZYKADIA patent cliff — loss of exclusivity December 2037 | CliffBio